CRISPR’s First Clinical Evidence for HBV cccDNA Elimination, Prime Editing Advances to Inaugural Human Trial

CRISPR Medicine News USA

Overview

Precision Biosciences’ PBGENE-HBV has demonstrated the first clinical evidence of eliminating viral cccDNA in chronic Hepatitis B patients, marking a significant milestone for CRISPR-based therapies in infectious disease. Concurrently, Prime Medicine initiated its first-in-human clinical trial for in vivo prime editing in New Zealand, advancing a next-generation gene editing technology that directly corrects disease-causing mutations. Further, Prime Medicine’s PM359 received FDA RMAT designation for p47phox-deficient Chronic Granulomatous Disease, and Intellia Therapeutics reported positive Phase 3 results for lonvo-z in hereditary angioedema. These rapid clinical advancements underscore the transformative potential of CRISPR technologies across diverse medical conditions.

In Depth

Key Findings

CRISPR gene editing technology has made significant strides in both infectious disease treatment and genetic disorders. Precision Biosciences’ hepatitis B therapy, PBGENE-HBV, has shown the first clinical evidence of eliminating viral cccDNA, while Prime Medicine’s in vivo prime editing therapy has commenced its first-in-human clinical trial in New Zealand. These developments indicate a rapid transition of next-generation therapeutic approaches into clinical application.

Technical / Clinical Details

In a Phase 1 clinical trial for chronic hepatitis B patients, Precision Biosciences’ PBGENE-HBV demonstrated its ability to effectively eliminate covalently closed circular DNA (cccDNA), which is essential for hepatitis B virus (HBV) replication. This marks the first clinical validation of a CRISPR-based technology targeting the root cause of an infectious disease, paving the way for novel strategies against viral infections. Meanwhile, Prime Medicine’s in vivo prime editing therapy, which directly rewrites specific base pairs in the genome, promises higher precision and safety compared to conventional CRISPR/Cas9 by avoiding double-strand breaks. The initial clinical trial in New Zealand aims to assess its safety and preliminary efficacy. Additionally, Prime Medicine’s PM359, a therapeutic candidate for p47phox-deficient Chronic Granulomatous Disease (CGD), a severe immunodeficiency, received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. Intellia Therapeutics’ lonvo-z, targeting hereditary angioedema (HAE), reported positive results in a Phase 3 clinical trial, showing significant reduction in HAE attack frequency compared to existing treatments.

Background & Context

CRISPR technology has emerged as a central tool in gene therapy over the past few years, known for its precision and efficiency as ‘molecular scissors’. Next-generation techniques like prime editing are particularly promising as they avoid double-strand breaks, reducing the risk of off-target effects and expanding applicability to a broader range of genetic disorders. The FDA’s RMAT designation is designed to expedite the development and review of innovative regenerative medicine products for serious conditions, with PM359’s designation validating its high therapeutic potential. The development of therapies for rare diseases like HAE not only dramatically improves patients’ quality of life but also solidifies the commercial success of gene therapies in the biopharmaceutical market.

Strategic Significance & Outlook

The success of these clinical trials suggests that CRISPR-based gene therapies can offer fundamental solutions for diseases where treatment options have been limited. Precision Biosciences’ achievement could broaden the potential applications of CRISPR to other viral infections, such as HIV. Prime Medicine’s prime editing technology, given its versatility, is expected to initiate trials for numerous other genetic disorders. As long-term safety and efficacy data accumulate for these technologies, gene therapy is poised to become a cornerstone of personalized medicine, bringing hope to many patients. Regulatory bodies will also need to continue adapting their review processes to accommodate these rapid technological innovations.

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

• Your email and selected fields are used only to deliver the newsletter.
• We never share your information with third parties.
• You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Agree & Continue ▶

Takes about a minute · Unsubscribe anytime